HYDROCHLOROTHIAZIDE tablet

البلد: الولايات المتحدة

اللغة: الإنجليزية

المصدر: NLM (National Library of Medicine)

العنصر النشط:

HYDROCHLOROTHIAZIDE (UNII: 0J48LPH2TH) (HYDROCHLOROTHIAZIDE - UNII:0J48LPH2TH)

متاح من:

Bryant Ranch Prepack

طريقة التعاطي:

ORAL

نوع الوصفة الطبية :

PRESCRIPTION DRUG

الخصائص العلاجية:

Hydrochlorothiazide tablets are indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Hydrochlorothiazide tablets have also been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. Hydrochlorothiazide tablets are indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension. Use in Pregnancy: Routine use of diuretics during normal pregnancy is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy and there is no satisfactory evidence that they are useful in the treatment of toxemia. Edema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy. Thiazides are indicated in pregnan

ملخص المنتج:

Product: 71335-1610 NDC: 71335-1610-0 120 TABLET in a BOTTLE NDC: 71335-1610-1 100 TABLET in a BOTTLE NDC: 71335-1610-2 30 TABLET in a BOTTLE NDC: 71335-1610-3 7 TABLET in a BOTTLE NDC: 71335-1610-4 14 TABLET in a BOTTLE NDC: 71335-1610-5 60 TABLET in a BOTTLE NDC: 71335-1610-6 2 TABLET in a BOTTLE NDC: 71335-1610-7 90 TABLET in a BOTTLE NDC: 71335-1610-8 4 TABLET in a BOTTLE NDC: 71335-1610-9 8 TABLET in a BOTTLE

الوضع إذن:

Abbreviated New Drug Application

خصائص المنتج

HYDROCHLOROTHIAZIDE- HYDROCHLOROTHIAZIDE TABLET
BRYANT RANCH PREPACK
----------
HYDROCHLOROTHIAZIDE TABLETS, USP
12.5 MG, 25 MG AND 50 MG
RX ONLY
DESCRIPTION:
Hydrochlorothiazide is a diuretic and antihypertensive. It is the
3,4-dihydro derivative of
chlorothiazide. It is chemically designated as 6-chloro-3,4-dihydro-2
_H_-1,2,4-benzothiadiazine-7-
sulfonamide 1,1-dioxide and has the following structural formula:
Hydrochlorothiazide, USP is a white, or practically white, crystalline
powder which is slightly soluble
in water, freely soluble in sodium hydroxide solution, in
n-butylamine, and in dimethylformamide;
sparingly soluble in methanol; insoluble in ether, in chloroform, and
in dilute mineral acids. Each tablet
for oral administration contains 12.5 mg, 25 mg or 50 mg
hydrochlorothiazide, USP. In addition, each
tablet contains the following inactive ingredients: dibasic calcium
phosphate dihydrate, FD & C yellow,
lactose monohydrate, magnesium stearate, pregelatinized starch (starch
1500) and sodium starch
glycolate.
CLINICAL PHARMACOLOGY:
The mechanism of the antihypertensive effect of thiazides is unknown.
Hydrochlorothiazide does not
usually affect normal blood pressure.
Hydrochlorothiazide affects the distal renal tubular mechanism of
electrolyte reabsorption. At maximal
therapeutic dosage all thiazides are approximately equal in their
diuretic efficacy.
Hydrochlorothiazide increases excretion of sodium and chloride in
approximately equivalent amounts.
Natriuresis may be accompanied by some loss of potassium and
bicarbonate.
After oral use diuresis begins within 2 hours, peaks in about 4 hours
and lasts about 6 to 12 hours.
PHARMACOKINETICS AND METABOLISM: Hydrochlorothiazide is not
metabolized but is eliminated rapidly
by the kidney. When plasma levels have been followed for at least 24
hours, the plasma half-life has
been observed to vary between 5.6 and 14.8 hours. At least 61% of the
oral dose is eliminated
unchanged within 24 hours. Hydrochlorothiazide crosses the placental
but not the blood-brain ba